EDAP TMS SA quarterly report, Q1 FY2026

EDAP TMS SA - 10-Q Filing Summary (Q1 2026)

Business Context and Reporting Period

This is the first quarterly report filed by EDAP TMS SA as a U.S. domestic issuer, covering the period ended March 31, 2026. The company develops and distributes non-invasive medical devices, primarily for urological diseases, organized into three segments: High Intensity Focused Ultrasound (HIFU), Lithotripsy (ESWL), and Distribution. Management has shifted strategy to prioritize HIFU growth while de-emphasizing ESWL and Distribution activities.

Key Financial Metrics

MetricQ1 2026Q1 2025
Total Revenue$17.8 million$14.3 million
Gross Profit$8.1 million$6.0 million
Gross Margin45.7%42.0%
Operating Loss$(7.4) million$(6.3) million
Net Loss$(9.1) million$(7.4) million
Diluted EPS$(0.24)$(0.20)
Cash and Equivalents (End of Period)$15.0 million$24.7 million
Operating Cash Flow$(3.0) million$(5.3) million
Total Debt (Current + Non-Current)$19.1 million$18.0 million

Material Changes vs. Prior Period

  • Revenue Growth: Total revenue increased 24.8% year-over-year, driven primarily by the HIFU division which grew 78.3% to $11.6 million. This was fueled by a 146.7% increase in medical device sales (11 Focal One units sold vs. 6 in Q1 2025).
  • Segment Performance: While HIFU surged, the ESWL division revenue declined 15.8% and the Distribution division declined 21.2%, consistent with the strategic pivot away from legacy businesses.
  • Expense Increases: Operating expenses rose 26% to $15.5 million. General and administrative expenses jumped 58.5% largely due to fees associated with transitioning to U.S. domestic filer status.
  • Financial Expenses: Net financial expense was $1.7 million, a significant increase from $15k income in the prior year. This was driven by a $1.3 million loss on the fair value adjustment of warrants issued to the European Investment Bank (EIB).
  • Liquidity: Cash reserves decreased by $5.4 million during the quarter. However, the company drew Tranche B of its EIB credit facility (€12 million) in April 2026 (subsequent event).

Outlook, Risks, and Management Commentary

  • Going Concern: Management states that while the recent EIB drawdown provides sufficient funds for at least 12 months, the company has a history of losses and may need to raise substantial additional financing to achieve profitability. There is uncertainty regarding the ability to raise capital on acceptable terms.
  • Strategic Focus: The company continues to focus on commercializing the Focal One robotic HIFU system, particularly in the U.S. market, while reducing emphasis on ESWL and Distribution.
  • Risks: Key risks include the ability to raise capital, regulatory approval uncertainties for HIFU devices, reimbursement status, intense competition, and foreign exchange fluctuations (Euro vs. USD/JPY).
  • Subsequent Events: On April 20, 2026, the company received €12 million from the EIB under Tranche B of its credit facility.

Investor Verification Checklist

  • Cash Runway: Verify the sufficiency of the €12 million EIB Tranche B proceeds against the current burn rate and the timeline to profitability.
  • HIFU Adoption: Confirm the sustainability of the 146.7% growth in Focal One unit sales and the conversion rate of leases/RPPs to capital sales.
  • Warrant Liability: Monitor the fair value volatility of the EIB warrants, which significantly impacted Q1 net loss and could continue to affect earnings.
  • Regulatory Status: Track the clinical and regulatory progress of HIFU devices in key markets, particularly the U.S., as this is central to the growth strategy.
  • Cost Structure: Assess whether the 58.5% increase in G&A expenses is a one-time transition cost or a new baseline for operating expenses.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.